Appendix

May 11, 2016

1 Model

1.1 Model structure

We developed a susceptible-infective-treated coinfection model with heterogeneous mixing. Model consists of 9 states which are classified by syphilis and HIV infection status: SS_i , IS_i , TS_i , SI_i , II_i , TI_i , ST_i , IT_i , and TT_i . Given a state XY_i , X represents the HIV infection status; Y represents the syphilis infection status; and i represents the risk group. For simplicity, we do not consider progression through different stages of the disease, and assume that there are only two risk groups: i=1,2.

We assume that all individuals leave at-risk population at a rate μ , and individuals enter at-risk population as SS (susceptible to both diseas) at a constant rate that is proportional to the proportion of each risk group at a disease-free equilibrium: μN_0 . Individuals infected syphilis receive treatment (acquiring partial immunity) at a rate γ and lose immunity (becoming susceptible) at a rate δ . Individuals infected with HIV receive ARV treatment at a rate τ . They can also leave ARV treament or treatment may fail (entering infective compartment) at a rate σ . Individuals infected with HIV die at a rate α but if they're receiving ARV treatment, they die at a slower rate of $\epsilon_{\alpha}\alpha$, where $\epsilon_{\alpha}<1$. Individuals infected with syphilis and HIV can infect a susceptible partner at a probability of β_{syph} and β_{HIV} per partnership, respectively. ARV treatment reduces HIV transmission rate by the factor of ϵ_{β} , and syphilis infection increases acuiqition and transmission rate of HIV by the factor of ν_r and ν_t , respectively (Deschamps et al., 1996; Røttingen et al., 2001). For simplicity, we do not consider explicit partnership dynamics but we assume assortative mixing.

1.2 Assortativity

Assortative mixing is modeled based on the work of Grassly et al. (2005). Proportion ρ of an individual's mixing is reserved for their own risk group, and the rest is used randomly in the whole population. Force of infection, λ_i , that susceptible individuals in a risk group, i, experience from a particular disease is given by the following equation:

$$\lambda_i = \rho \beta_i \frac{Y_i}{N_i} + (1 - \rho) \beta_i \frac{\sum_i c_i Y_i}{\sum_i c_i N_i},\tag{1}$$

where i is the mixing group, c_i is the partnership rate, N_i is total number of people in the mixing group, and $\beta_i = \beta * c_i$ (β is the transmission probability per partnership of the disease).

1.3 Transmission

In the equations introduced above, Y_i is the number of individuals in a risk group i that are infected with a particular disease. However, in order to account for varying transmissibility depending on the infection status, We define $J_i^{HIV} = IS_i + \nu_t II_i + IT_i + \epsilon_\beta (TS_i + \nu_t TI_i + TT_i)$ and $J_i^{syph} = SI_i + II_i + TI_i$, which are used to calculate force of infection of two diseases:

$$\lambda_{i}^{HIV} = \rho \beta_{i}^{HIV} \frac{J_{i}^{HIV}}{N_{i}} + (1 - \rho) \beta_{i}^{HIV} \frac{\sum_{i} c_{i} J_{i}^{HIV}}{\sum_{i} c_{i} N_{i}},$$

$$\lambda_{i}^{syph} = \rho \beta_{i}^{syph} \frac{J_{i}^{syph}}{N_{i}} + (1 - \rho) \beta_{i}^{syph} \frac{\sum_{i} c_{i} J_{i}^{syph}}{\sum_{i} c_{i} N_{i}}.$$
(2)

Increased susceptibility to HIV due to syphilis is modeled by multiplying the term ν_r to the infection term going from SI_i to II_i : $SI_i' = -\nu_r \lambda_i^{HIV} SI_i$ and $II_i' = -\nu_r \lambda_i^{HIV} SI_i$.

1.4 Mathematical model

$$SS'_{i} = \mu N(0)_{i} - (\lambda_{i}^{HIV} + \lambda_{i}^{syph})SS_{i} + \delta ST_{i} - \mu SS_{i}$$

$$IS'_{i} = -\lambda_{i}^{syph}IS_{i} + \lambda_{i}^{HIV}SS_{i} - \tau IS_{i} + \sigma TS_{i} + \delta IT_{i} - \alpha IS_{i} - \mu IS_{i}$$

$$TS'_{i} = -\lambda_{i}^{syph}TS_{i} + \tau IS_{i} - \sigma TS_{i} + \delta TT_{i} - \epsilon_{\alpha}\alpha TS_{i} - \mu TS_{i}$$

$$SI'_{i} = -\nu_{r}\lambda_{i}^{HIV}SI_{i} + \lambda_{i}^{syph}SS_{i} - \gamma SI_{i} - \mu SI_{i}$$

$$II'_{i} = \nu_{r}\lambda_{i}^{HIV}SI_{i} + \lambda_{i}^{syph}IS_{i} - \tau II_{i} + \sigma TI_{i} - \gamma II_{i} - \alpha II_{i} - \mu II_{i}$$

$$TI'_{i} = \lambda_{i}^{syph}TS_{i} + \tau II_{i} - \sigma_{i}TI_{i} - \gamma TI_{i} - \epsilon_{\alpha}\alpha TI_{i} - \mu TI_{i}$$

$$ST'_{i} = -\lambda_{i}^{HIV}ST_{i} + \gamma SI_{i} - \delta ST_{i} - \mu ST_{i}$$

$$IT'_{i} = \lambda_{i}^{HIV}ST_{i} - \tau IT_{i} + \sigma TT_{i} + \gamma II_{i} - \delta IT_{i} - \alpha IT_{i} - \mu IT_{i}$$

$$TT'_{i} = \tau IT_{i} - \sigma TT_{i} + \gamma TI_{i} - \delta TT_{i} - \epsilon_{\alpha}\alpha TT_{i} - \mu TT_{i}$$

1.5 Delayed introduction of ARV

Instead of using the model as it is above, we introduce ARV treatment 20 years after the beginning of the simulation. It is simply done by multiplying T_{start} to τ ($\tau_{adj} = T_{start}\tau$) and setting $T_{start} = 0$ when t < 20 and 1 otherwise. With the introduction of ARV, we introduce two more variables to the model: ν_{IS}

and c_{inc} . ν_{IS} is the ratio of increased susceptibility to syphilis due to ARV immunosuppression effect and c_{inc} is the effect of ARV on behaviour (also given as a ratio). ν_{IS} is simply multiplied to syphilis infection term going from TS_i to TI_i . $TS_i' = -\nu_{IS}\lambda_i^{syph}TS_i$ and $TI_i' = \nu_{IS}\lambda_i^{syph}TS_i$.

With the introdction of ARV, behaviour change is introduced to people who are receiving ARV. The behaviour change is modeled by multiplying c_{inc} to the partnership change rate of those who are receiving ARV. It is done by modifying J, N, as well as the infection term going from TS_i to TI_i :

$$\begin{split} J_{i}^{HIV} &= IS_{i} + \nu_{t}II_{i} + IT_{i} + c_{inc}\epsilon_{\beta}(TS_{i} + \nu_{t}TI_{i} + TT_{i}), \\ J_{i}^{syph} &= SI_{i} + II_{i} + c_{inc}TI_{i}, \\ N_{i} &= SS_{i} + IS_{i} + SI_{i} + II_{i} + ST_{i} + TT_{i} + c_{inc}(TS_{i} + TI_{i} + TT_{i}) \\ TS'_{i} &= -c_{inc}\nu_{IS}\lambda_{i}^{syph}TS_{i} \\ TI'_{i} &= c_{inc}\nu_{IS}\lambda_{i}^{syph}TS_{i}. \end{split} \tag{4}$$

Increase in behaviour change is modeled by using the exponential function: $c_{inc} = c_f + (c_0 - c_f) exp((T_{start} - t)/T_c)$. These equations replace the equations in the above model.

References

- Champredon, D., S. Bellan, and J. Dushoff (2013). Hiv sexual transmission is predominantly driven by single individuals rather than discordant couples: a model-based approach. *PloS one* 8(12), e82906.
- Cohen, M. S., Y. Q. Chen, M. McCauley, T. Gamble, M. C. Hosseinipour, N. Kumarasamy, J. G. Hakim, J. Kumwenda, B. Grinsztejn, J. H. Pilotto, et al. (2011). Prevention of hiv-1 infection with early antiretroviral therapy. *New England journal of medicine* 365(6), 493–505.
- Collaboration, H.-C. et al. (2010). The effect of combined antiretroviral therapy on the overall mortality of hiv-infected individuals. *AIDS* (*London*, *England*) 24(1), 123.
- Deschamps, M.-M., J. W. Pape, A. Hafner, and W. D. Johnson (1996). Heterosexual transmission of hiv in haiti. *Annals of internal medicine* 125(4), 324–330.
- Garnett, G. P., S. O. Aral, D. V. Hoyle, W. Cates Jr, and R. M. Anderson (1997). The natural history of syphilis: implications for the transmission dynamics and control of infection. *Sexually transmitted diseases* 24(4), 185–200.
- Granich, R. M., C. F. Gilks, C. Dye, K. M. De Cock, and B. G. Williams (2009). Universal voluntary hiv testing with immediate antiretroviral therapy as a strategy for elimination of hiv transmission: a mathematical model. *The Lancet* 373(9657), 48–57.

- Grant, R. M., J. A. Wiley, and W. Winkelstein (1987). Infectivity of the human immunodeficiency virus: estimates from a prospective study of homosexual men. *The Journal of infectious diseases* 156(1), 189–193.
- Grassly, N. C., C. Fraser, and G. P. Garnett (2005). Host immunity and synchronized epidemics of syphilis across the united states. *Nature* 433(7024), 417–421.
- Røttingen, J.-A., D. W. Cameron, and G. P. Garnett (2001). A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and hiv: how much really is known? *Sexually transmitted diseases* 28(10), 579–597.

Table 1: Parameter values

Notation	Description	Value(s)	Source
\overline{c}	Partnership change rate	40 and 5	Garnett et al. (1997)
N_0	Proportion of risk group	0.05 and 0.95	Assumption
ho	Proportion of non-random con-	0.3	Assumption
	tact		
μ	Rate of entry/exit from at risk	0.05	Garnett et al. (1997)
	population		
β_{HIV}	HIV transmission probability	0.097	Grant et al. (1987)
	per partnership		
ϵ_eta	Relative HIV transmission ratio	0.04	Cohen et al. (2011)
	of people on ART		
α	HIV induced mortality	0.125	Champredon et al. (2013)
ϵ_{lpha}	Relative mortality ratio of people	0.5	Collaboration et al. (2010)
	on ART		
au	ART treatment rate	1	Granich et al. (2009)
σ	ART failure/loss rate	0.015	Granich et al. (2009)
β_{syph}	Syphilis transmission probabil-	0.6	Garnett et al. (1997)
	ity per partnership		
γ	Syphilis treatment rate	6	Grassly et al. (2005)
δ	Rate at which syphilis immunity	0.05	Grassly et al. (2005)
	is lost		
$ u_t$	Relative HIV transmission ratio	2	Deschamps et al. (1996)
	of people who are infected with		
	syphilis		
$ u_r$	Relative HIV acquisition ratio of	3	Røttingen et al. (2001)
	people who are infected with		
	syphilis		
$ u_{is}$	Relative syphilis acquiring ratio	3	Assumption
	due to ARV immunosuppression		